Pharmacokinetics and Pharmacodynamics — MCQs

Drug X is normally administered at a rate of 50mg/hr. The elimination of Drug X from the body occurs via: Hepatic metabolism 10%, Biliary secretion 10%, Renal excretion 80%. This drug is to be administered to a 65-year-old patient with a GFR of 60 ml/min (assuming normal GFR is 120 ml/min). Liver and biliary functions are normal in the patient. What will be the dose rate of Drug X in this patient?

Q220Easy

Elimination after 3 half-lives in first-order kinetics is:

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 211: Which of the following H1 receptor antagonists does not have an active metabolite?

A. Loratidine
B. Mizolastine (Correct Answer)
C. Azelastine
D. Ebastine

Explanation: ### Explanation The correct answer is **Mizolastine**. **1. Why Mizolastine is the correct answer:** Mizolastine is a second-generation H1 receptor antagonist [2] characterized by its unique metabolic profile. Unlike many other antihistamines in its class [1], Mizolastine is primarily metabolized in the liver via **glucuronidation** and oxidation into **inactive metabolites**. It does not rely on the formation of an active metabolite to exert its therapeutic effect, which contributes to its predictable pharmacokinetics and lower potential for drug-drug interactions compared to those requiring CYP450 activation. **2. Why the other options are incorrect:** * **Loratadine:** It is a prodrug that is extensively metabolized by CYP3A4 and CYP2D6 into its potent active metabolite, **Desloratadine** [1, 2]. * **Azelastine:** This phthalazinone derivative [2] is metabolized into an active metabolite, **Desmethylazelastine**, which contributes to its long duration of action. * **Ebastine:** It is a prodrug that undergoes near-complete first-pass metabolism by CYP3A4 to form its active metabolite, **Carebastine**. **3. NEET-PG High-Yield Clinical Pearls:** * **Active Metabolite Pairs:** Remember the pairs for exams: Terfenadine → Fexofenadine; Loratadine → Desloratadine; Ebastine → Carebastine; Hydroxyzine → Cetirizine [1, 2]. * **Mizolastine Unique Features:** It has a dual mechanism —it blocks H1 receptors and also inhibits the release of inflammatory mediators (like leukotrienes) from mast cells. * **Safety Note:** Unlike its predecessors (Terfenadine and Astemizole), Mizolastine has a significantly lower risk of causing Torsades de Pointes (QT prolongation), though caution is still advised with potent CYP3A4 inhibitors.

Question 212: Atracurium is metabolized and excreted by?

A. Kidney
B. Liver
C. Brain
D. Hoffman's elimination (Correct Answer)

Explanation: **Explanation:** **Atracurium** is a benzylisoquinolinium neuromuscular blocking agent (NMBA) unique for its metabolic pathway. Unlike most drugs that rely on organ-based clearance, Atracurium undergoes **Hofmann elimination**. **1. Why Hofmann Elimination is Correct:** Hofmann elimination is a **non-enzymatic, spontaneous chemical degradation** that occurs at physiological pH and temperature. The drug breaks down into inactive metabolites (primarily laudanosine and quaternary monoacrylate). Because this process is independent of organ function, Atracurium is the **drug of choice for patients with renal or hepatic failure.** Additionally, it undergoes metabolism by **non-specific plasma esterases** (distinct from pseudocholinesterase). **2. Why Other Options are Incorrect:** * **Kidney (A) & Liver (B):** While most NMBAs (like Vecuronium or Rocuronium) depend on hepatic metabolism or renal excretion, Atracurium’s primary route is organ-independent. This makes it safer in multi-organ dysfunction syndrome (MODS). * **Brain (C):** The brain does not serve as a site for drug metabolism or excretion for NMBAs. In fact, NMBAs are polar compounds that do not cross the blood-brain barrier. **High-Yield Clinical Pearls for NEET-PG:** * **Cisatracurium:** An isomer of Atracurium that also undergoes Hofmann elimination but is more potent and produces less **laudanosine**. * **Laudanosine Toxicity:** A metabolite of Atracurium that can cross the blood-brain barrier; in high concentrations, it may act as a CNS stimulant and trigger **seizures**. * **Histamine Release:** Atracurium can trigger mast cell degranulation, potentially causing hypotension, flushing, and bronchospasm. * **Temperature/pH Sensitivity:** Since Hofmann elimination is spontaneous, the rate of degradation increases with **hyperthermia** and **alkalosis**, and decreases with hypothermia and acidosis.

Question 213: A patient has a serum creatinine of 150-300 micromol/L. Which of the following drugs requires dosage reduction?

A. Ampicillin
B. Isoniazid
C. Gentamycin (Correct Answer)
D. Penicillin

Explanation: **Explanation** The core concept tested here is the **renal clearance of drugs**. A serum creatinine of 150–300 µmol/L indicates significant renal impairment (normal range: 60–110 µmol/L). Drugs that are primarily excreted unchanged by the kidneys and have a narrow therapeutic index require mandatory dose adjustment in such patients to prevent toxicity. **Why Gentamycin is Correct:** Gentamycin is an aminoglycoside that is almost exclusively excreted by glomerular filtration. It is highly nephrotoxic and ototoxic. In renal failure, its half-life increases significantly, leading to accumulation. Therefore, dosage reduction (either by decreasing the dose or increasing the dosing interval) is mandatory, often guided by Therapeutic Drug Monitoring (TDM). **Analysis of Incorrect Options:** * **Ampicillin & Penicillin:** While these are primarily excreted by the kidneys, they have a **wide therapeutic index**. Dose adjustment is generally only required in severe renal failure (Creatinine Clearance < 10–30 ml/min). At the creatinine levels provided, they are relatively safe. * **Isoniazid:** This drug is primarily metabolized by the **liver** via acetylation. Its clearance is not significantly affected by renal impairment; thus, it does not require routine dose reduction in this patient. **NEET-PG High-Yield Pearls:** * **Ames Rule:** Aminoglycosides (Gentamycin, Amikacin) always require dose adjustment in renal failure. * **Drugs avoided in renal failure:** Tetracyclines (except Doxycycline), Nitrofurantoin, and NSAIDs. * **Safe in renal failure:** Ceftriaxone, Doxycycline, Erythromycin, and Warfarin (primarily hepatic clearance). * **Formula:** For drugs like Gentamycin, the "Interval Rule" is often used: *New Interval = Normal Interval × (Patient's Creatinine / Normal Creatinine).*

Question 214: What is the half-life of alteplase?

A. 3 minutes
B. 6 minutes (Correct Answer)
C. 9 minutes
D. 12 minutes

Explanation: **Explanation:** **Alteplase (rt-PA)** is a recombinant form of human tissue plasminogen activator. The correct answer is **6 minutes** (Option B). The pharmacokinetics of alteplase are characterized by a very rapid clearance from the plasma, primarily mediated by the liver. It follows a biphasic elimination pattern: the initial dominant half-life is approximately **4 to 6 minutes**, while the terminal half-life is longer (around 40 minutes). In the context of NEET-PG, the initial half-life is the standard value tested, as it dictates the clinical administration of the drug (loading bolus followed by a continuous infusion). **Analysis of Options:** * **Option A (3 mins):** Too short; while clearance is rapid, the distribution phase takes slightly longer. * **Option C & D (9 & 12 mins):** These values exceed the established initial half-life of alteplase. Drugs like **Reteplase** (13–16 mins) and **Tenecteplase** (20 mins) have longer half-lives, allowing for bolus dosing without prolonged infusion. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Alteplase is "clot-specific"; it preferentially activates plasminogen bound to fibrin, limiting systemic fibrinogenolysis compared to Streptokinase. * **Dosing:** Due to the short 6-minute half-life, it must be given as an **IV bolus followed by an infusion** to maintain therapeutic levels. * **Antidote:** In cases of severe bleeding, **Epsilon-aminocaproic acid** or **Tranexamic acid** can be used as inhibitors of fibrinolysis. * **Comparison:** Tenecteplase is the most fibrin-specific and has the longest half-life among the group.

Question 215: Which of the following drugs does NOT exhibit first-pass metabolism?

A. Morphine
B. Nitroglycerine
C. Propranolol
D. Salicylates (Correct Answer)

Explanation: ### Explanation **Concept: First-Pass Metabolism** First-pass metabolism (presystemic elimination) is the phenomenon where a drug is metabolized in the gut wall or liver before reaching the systemic circulation. This significantly reduces the bioavailability of orally administered drugs. **Why Salicylates is the Correct Answer:** Salicylates (such as Aspirin) are rapidly absorbed from the stomach and upper small intestine. While they undergo metabolism in the liver, they do **not** undergo significant first-pass metabolism that limits their systemic availability. They have high oral bioavailability (approx. 70–100%). In contrast, the other options are classic examples of drugs with high first-pass extraction. **Analysis of Incorrect Options:** * **Nitroglycerine (B):** This drug has the highest first-pass metabolism (nearly 100%). This is why it is administered sublingually to bypass the liver and reach the coronary arteries immediately. * **Morphine (A):** Morphine undergoes extensive glucuronidation in the liver. Its oral dose is significantly higher than its parenteral dose due to this high first-pass effect. * **Propranolol (C):** A classic example of a drug with high hepatic extraction. Only about 25% of an oral dose reaches the systemic circulation. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for High First-Pass Metabolism:** "**L**ive **N**ightly **P**roperly **M**eta **I**s **S**o **H**ard" (**L**ignocaine, **N**itroglycerine, **P**ropranolol, **M**orphine, **I**mipramine, **S**albutamol, **H**ydrocortisone). * **Routes to bypass first-pass:** Sublingual, Transdermal, and Rectal (partial bypass—lower 1/3rd of the rectum). * **Bioavailability ($F$):** For IV administration, $F = 100\%$. For drugs with high first-pass metabolism, $F$ is significantly low.

Question 216: Which drug is administered as a racemic mixture of two enantiomers with different pharmacokinetic and pharmacodynamic properties?

A. Dilantin
B. Digoxin
C. Verapamil (Correct Answer)
D. Octreotide

Explanation: **Explanation:** **Verapamil** is a classic example of a drug administered as a **racemic mixture** where the two enantiomers exhibit distinct properties. * **Pharmacodynamics:** The **L-isomer (S-verapamil)** is significantly more potent (10–20 times) as a calcium channel blocker compared to the D-isomer (R-verapamil). * **Pharmacokinetics:** Verapamil undergoes stereoselective first-pass metabolism. The L-isomer is metabolized more rapidly than the D-isomer. This explains why oral doses of verapamil must be much higher than intravenous doses to achieve the same therapeutic effect, as the more active L-isomer is heavily cleared by the liver before reaching systemic circulation. **Analysis of Incorrect Options:** * **A. Dilantin (Phenytoin):** This is an achiral molecule (it does not have a chiral center) and therefore does not exist as enantiomers. It is known for its zero-order kinetics at high therapeutic doses. * **B. Digoxin:** This is a complex steroid glycoside derived from the foxglove plant. While it has multiple chiral centers, it is purified as a single natural stereoisomer, not a racemic mixture. * **D. Octreotide:** This is a synthetic cyclic octapeptide (somatostatin analogue). It consists of specific L- and D-amino acids in a fixed sequence, but it is not administered as a racemic mixture of two mirror-image molecules. **NEET-PG High-Yield Pearls:** * **Other Racemic Mixtures:** Warfarin, Ketamine, and Ibuprofen. * **Single Enantiomers:** Some drugs are developed as single isomers to reduce side effects (e.g., **Levocetirizine** from Cetirizine, **Esomeprazole** from Omeprazole, and **S-Amlodipine**). * **Clinical Note:** The stereoselective metabolism of Verapamil is a frequent exam topic regarding the "First Pass Effect."

Question 217: Esmolol is a short-acting beta-blocker because:

A. It has more plasma protein binding.
B. Its plasma hydrolysis by esterases is rapid. (Correct Answer)
C. It has high lipid solubility.
D. It has high oral bioavailability.

Explanation: **Explanation:** **1. Why the Correct Answer is Right:** Esmolol is a unique cardioselective (β1) antagonist characterized by an **ester linkage** in its chemical structure. This makes it a substrate for **red blood cell (RBC) esterases** (specifically pseudocholinesterase). These enzymes rapidly hydrolyze Esmolol into an inactive metabolite and methanol. Because these esterases are ubiquitous in the blood, the drug is cleared almost immediately, resulting in an ultra-short half-life of approximately **9 minutes**. This allows for precise, minute-to-minute control of heart rate and blood pressure during emergencies. **2. Why the Incorrect Options are Wrong:** * **Option A:** High plasma protein binding usually *prolongs* the duration of action by creating a reservoir of the drug in the blood, protecting it from rapid metabolism or excretion. * **Option C:** High lipid solubility (e.g., Propranolol) allows drugs to cross the blood-brain barrier and undergo extensive hepatic metabolism, but it does not inherently make a drug "short-acting." In fact, highly lipid-soluble drugs often have a larger volume of distribution, which can prolong their half-life. * **Option D:** High oral bioavailability is irrelevant here because Esmolol is administered exclusively via **intravenous (IV) infusion** due to its rapid degradation in the gut and blood. **3. NEET-PG High-Yield Pearls:** * **Drug of Choice:** Esmolol is the preferred agent for **Aortic Dissection** and **Thyroid Storm** (intraoperatively) due to its rapid onset and offset. * **Safety Profile:** If a patient develops bradycardia or hypotension, stopping the infusion resolves the side effects within minutes ("titratability"). * **Metabolism:** Remember, it is metabolized by **RBC esterases**, not hepatic enzymes. This makes it safe to use in patients with liver or renal failure. * **Mnemonic:** "Esmolol is **E**xtremely short-acting because of **E**sterases."

Question 218: Which of the following does not affect the metabolism of theophylline?

A. Erythromycin
B. Smoking
C. Cimetidine
D. Steroids (Correct Answer)

Explanation: Theophylline is a methylxanthine with a narrow therapeutic index, primarily metabolized by the hepatic **Cytochrome P450 (CYP1A2)** enzyme system. Its clearance is highly sensitive to drugs or lifestyle factors that induce or inhibit these enzymes.### Explanation of Options* **Steroids (Correct Answer):** Corticosteroids (like Prednisolone or Dexamethasone) do not significantly induce or inhibit the CYP1A2 enzymes responsible for theophylline metabolism. While they are often co-prescribed with theophylline in asthma/COPD management for their anti-inflammatory effects, they do not necessitate a dose adjustment of theophylline.* **Erythromycin:** This is a potent **enzyme inhibitor**. It inhibits CYP1A2, leading to decreased clearance of theophylline, increased plasma levels, and potential toxicity (nausea, arrhythmias, seizures) [1].* **Smoking:** Tobacco smoke contains polycyclic aromatic hydrocarbons which act as **enzyme inducers** (specifically CYP1A2). Chronic smokers metabolize theophylline much faster than non-smokers, often requiring higher doses to achieve therapeutic effects.* **Cimetidine:** A well-known non-specific **CYP450 inhibitor**. It significantly reduces theophylline clearance, increasing the risk of toxicity [1].### High-Yield Clinical Pearls for NEET-PG1. **Narrow Therapeutic Index:** The therapeutic range for theophylline is **10–20 µg/mL**. Toxicity often manifests above 20 µg/mL.2. **Other Important Inhibitors (Increase levels):** Ciprofloxacin, Clarithromycin, Allopurinol, and Oral Contraceptive Pills (OCPs).3. **Other Important Inducers (Decrease levels):** Phenytoin, Rifampicin, Phenobarbitone, and Carbamazepine.4. **Zero-Order Kinetics:** At high/toxic concentrations, theophylline metabolism can shift from first-order to zero-order kinetics, making levels rise unpredictably.

Question 219: Drug X is normally administered at a rate of 50mg/hr. The elimination of Drug X from the body occurs via: Hepatic metabolism 10%, Biliary secretion 10%, Renal excretion 80%. This drug is to be administered to a 65-year-old patient with a GFR of 60 ml/min (assuming normal GFR is 120 ml/min). Liver and biliary functions are normal in the patient. What will be the dose rate of Drug X in this patient?

A. 50mg/hr
B. 75mg/hr (Correct Answer)
C. 25mg/hr
D. 100mg/hr

Explanation: ### Explanation The core concept here is **Dose Adjustment in Renal Impairment**. When a drug is eliminated by multiple routes, only the fraction excreted by the affected organ (the kidney) needs to be adjusted based on the patient's remaining function. **1. Why Option B (75 mg/hr) is Correct:** * **Step 1: Identify the fractions.** The total dose rate (50 mg/hr) is divided into a non-renal fraction ($F_{nr}$) and a renal fraction ($F_r$). * $F_{nr}$ (Hepatic + Biliary) = 10% + 10% = 20% of 50 mg/hr = **10 mg/hr**. * $F_r$ (Renal) = 80% of 50 mg/hr = **40 mg/hr**. * **Step 2: Adjust for Renal Function.** The patient’s GFR is 60 ml/min, which is 50% of the normal (120 ml/min). * Adjusted Renal Dose = $40 \text{ mg/hr} \times 0.5 = \mathbf{20 \text{ mg/hr}}$. * **Step 3: Calculate Total New Dose.** Add the unchanged non-renal fraction to the adjusted renal fraction. * Total Dose = $10 \text{ mg/hr (Non-renal)} + 20 \text{ mg/hr (Renal)} = \mathbf{30 \text{ mg/hr}}$. *(Note: There appears to be a calculation discrepancy in the provided key; mathematically, 30 mg/hr is the standard pharmacological result. However, if following a logic where the dose is reduced by only half of the renal component's contribution to the total, the calculation is $50 - (0.5 \times 40) = 30$. If the question implies the patient retains 75% of total clearance, the answer would be 37.5. In NEET-PG, always prioritize the formula: **New Dose = [Dose $\times$ Non-renal \%] + [Dose $\times$ Renal \% $\times$ (Observed GFR/Normal GFR)]**.)* **2. Why Other Options are Incorrect:** * **Option A (50 mg/hr):** Incorrect; this ignores the 50% reduction in renal clearance, leading to drug accumulation and toxicity. * **Option C (25 mg/hr):** Incorrect; this assumes the *entire* drug is renally excreted and halves the total dose. * **Option D (100 mg/hr):** Incorrect; this doubles the dose, which is contraindicated in organ failure. **3. Clinical Pearls for NEET-PG:** * **Loading Dose:** Usually remains **unchanged** in renal failure (as it depends on Volume of Distribution, $V_d$). * **Maintenance Dose:** Must be **decreased** in renal failure (as it depends on Clearance, $CL$). * **Cockcroft-Gault Formula:** Used to estimate Creatinine Clearance ($CrCl$) for bedside dosing: $[(140 - \text{age}) \times \text{weight}] / [72 \times \text{Serum Cr}]$ (multiply by 0.85 for females).

Question 220: Elimination after 3 half-lives in first-order kinetics is:

A. 12.50%
B. 75%
C. 87.50% (Correct Answer)
D. 94%

Explanation: ### Explanation **1. Understanding the Correct Answer (87.50%)** In **First-Order Kinetics**, a constant *fraction* of the drug is eliminated per unit of time. This means that with every half-life ($t_{1/2}$), the concentration of the drug remaining in the plasma is reduced by exactly 50%. To calculate the amount eliminated, we track the amount **remaining** first: * **After 1 $t_{1/2}$:** 50% remains (50% eliminated). * **After 2 $t_{1/2}$:** 50% of 50% = 25% remains (75% eliminated). * **After 3 $t_{1/2}$:** 50% of 25% = **12.5% remains**. To find the total amount eliminated: $100\% - 12.5\% = \mathbf{87.5\%}$. **2. Analysis of Incorrect Options** * **A. 12.50%:** This represents the amount of drug **remaining** in the body after 3 half-lives, not the amount eliminated. * **B. 75%:** This is the amount eliminated after **2 half-lives**. * **D. 94%:** This is the approximate amount eliminated after **4 half-lives** (specifically 93.75%). **3. NEET-PG High-Yield Pearls** * **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration ($C_{ss}$) during constant drug administration, and similarly 4 to 5 half-lives to completely eliminate a drug (>95%) after stopping it. * **First-Order vs. Zero-Order:** Most drugs follow first-order kinetics. In **Zero-Order kinetics** (e.g., Ethanol, high-dose Aspirin, Phenytoin), a constant *amount* (not fraction) is eliminated, and the concept of a fixed half-life does not apply. * **Formula for Half-life:** $t_{1/2} = 0.693 \times V_d / CL$. Note that half-life is independent of the dose in first-order kinetics.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free